EU Sunscreen Regulation vs FDA OTC Monograph: Why European SPF Formulations Need a US-Specific Rethink

A French skincare brand came to us last year with a well-engineered SPF 50+ facial serum — photostable, consumer-tested, already selling well in Germany, Italy, and Spain. Their US distributor had lined up three regional retailers. Then their regulatory counsel in New York delivered the news: two of the UV filters in the product, Tinosorb S and Mexoryl SX, are not permitted under the FDA OTC monograph. To enter the US market with SPF claims, they needed an entirely different formulation.

That conversation happens more often than it should. The EU and the United States do not share a regulatory framework for sun protection products, and the divergence runs far deeper than a labelling tweak or a different SPF test method. For European brands preparing to export sunscreens or SPF-boosted skincare to the American market, understanding the structural difference between these two systems is step one of any serious market-entry plan.

A Cosmetic in Europe, a Drug in the United States

Under Regulation (EC) No 1223/2009, sunscreen products are cosmetics. A product that filters UV radiation and protects skin from sun damage sits in the same regulatory category as a moisturiser or a shampoo. The approved UV filters are listed in Annex VI of the regulation. If your formulation uses only those listed filters at or below the permitted maximum concentrations, your product can be placed on the market across all EU member states without pre-market authorisation from any regulatory body.

The United States takes a fundamentally different position. The FDA classifies sunscreens as Over-the-Counter (OTC) drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act). That classification triggers an entirely different regulatory regime, governed by a monograph system under 21 CFR Part 352: specific approved active ingredients, mandatory Drug Facts labelling, defined testing protocols, and concentration limits set by the FDA rather than a European commission. No pre-market approval is required for products that comply with the monograph — but compliance is non-negotiable.

This is not a bureaucratic technicality. It determines which ingredients you can use, what your label must say, how efficacy is tested, and which regulatory body has jurisdiction over your finished product. Clearing EU Regulation 1223/2009 means you’ve satisfied European cosmetics law. It does not bring you one step closer to US compliance.

The UV Filter Divide: What’s Approved in the EU That Isn’t in the US

EU Annex VI currently lists more than 25 approved UV filter substances, with maximum permitted concentrations ranging from 0.5% to 25% depending on the compound. European formulators have access to a broader, more recently approved toolkit than their US counterparts — particularly in the category of high-performance organic filters. Several of the most effective are simply absent from the FDA OTC monograph:

• Bemotrizinol (Tinosorb S) — a photostable broad-spectrum filter widely used in European SPF formulas, not on the FDA monograph
• Bisoctrizol (Tinosorb M) — a micronised hybrid filter, approved in Annex VI, not available to US formulators through the OTC pathway
• Ecamsule (Mexoryl SX) — a UVA filter developed by L’Oréal, approved under Annex VI; accessible in the US only through one licensed product (Anthelios SX) via a New Drug Application, not through the general monograph
• Drometrizole trisiloxane (Mexoryl XL) — same regulatory status as ecamsule

The FDA tried to close this gap with the Sunscreen Innovation Act (SIA) of 2014, which created an administrative pathway for new UV filter submissions. As of mid-2026, that pathway has yielded zero newly approved UV filters in the United States. Eight filters were formally submitted; none has cleared the process.

The 2019 FDA proposed rule added a further layer of complexity. It proposed classifying zinc oxide and titanium dioxide as GRASE (generally recognised as safe and effective) while placing 12 commonly used organic UV filters — including octinoxate, oxybenzone, and homosalate — into a “insufficient data” category requiring additional safety information before they could be confirmed GRASE. That rule was never finalised. The result is a US sunscreen market operating under regulatory ambiguity that has persisted for years — and one where European brands relying on EU-specific UV filters face a reformulation requirement, not a paperwork one, before any US launch.

What US Sunscreen Compliance Actually Requires

For a European brand entering the US market, the compliance work extends well beyond swapping UV filters.

Labelling. US sunscreens must carry a Drug Facts panel — an FDA-mandated format that specifies active ingredients (not INCI names as required under EU 1223/2009), purpose, directions, warnings, and inactive ingredients in a defined order and font size. The EU approach — SPF claim on the front panel, INCI list on the back, star-rating UVA symbol — does not satisfy FDA OTC labelling requirements. A US-facing product label is effectively a complete redesign, not a translation.

SPF testing. The EU relies on ISO 24444 for in-vivo SPF measurement and ISO 24443 for in-vitro UVA determination. The FDA requires compliance with its own SPF test protocol, which differs from ISO 24444 in procedural details including the reference sunscreen used and the dose application method. A product tested exclusively to ISO methods does not automatically satisfy FDA requirements. Brands typically need US-protocol SPF testing run by a lab with FDA-methodology capability — independent of whatever testing is already in the EU Product Information File.

Broad spectrum designation. The FDA’s “broad spectrum” claim requires passing a specific critical wavelength test (≥ 370 nm) combined with an SPF ≥ 15. The EU’s circled UVA symbol is issued based on meeting a UVA-to-UVB ratio criterion. These are different tests with different thresholds, and a product carrying the EU UVA marking cannot assume it will pass the FDA broad spectrum test without separate in-vitro verification.

MoCRA registration. Under the Modernization of Cosmetics Regulation Act (signed December 2022), cosmetic manufacturers and importers must register their facilities with the FDA and list their cosmetic products. Sunscreens, as OTC drugs, have long been subject to FDA facility registration under 21 CFR Part 207 — a separate track. European brands that sell both SPF and non-SPF products in the US need to manage both registration frameworks simultaneously.

The Practical Path for European Sun Care Brands

The most workable approach for European brands that want a US presence without running entirely separate global supply chains is a US-specific SKU: a reformulated version of the product using only UV filters on the FDA’s permitted list at compliant concentrations, tested under FDA protocols, and labelled to OTC Drug Facts standards.

The list of filters available under the current FDA framework includes avobenzone, octinoxate, octisalate, octocrylene, homosalate, oxybenzone, zinc oxide, and titanium dioxide, among others — a shorter but still functional palette for broad-spectrum formulation. Zinc oxide and titanium dioxide in particular offer photostability that partially compensates for the absence of EU-exclusive filters.

The timeline for this process is real: typically 9 to 18 months from reformulation start to market-ready inventory, depending on supply chain decisions, UV filter sourcing, and the testing queue at a qualifying US lab. Brands that build this into their internationalisation roadmap manage it without disruption. Those who discover the requirement after signing with a US distributor rarely do.

The starting point is a gap analysis: mapping your existing EU formulation against the FDA OTC monograph, identifying which UV filters need to be substituted, assessing how reformulation affects SPF performance and photostability, and scoping the full US testing package for your intended label claims. That work takes days. The decisions it drives — on formulation, on contract manufacturing, on testing partners — take months to execute. Starting early is the only variable you actually control.

Our team works with European sun care brands at exactly this juncture, connecting EU regulatory due diligence to US market-entry testing through our partner-lab network. If a US launch is on your roadmap for the next 18 months, the formulation conversation needs to happen now.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry Contact us

Related from our network

• FDA OTC Drug Compliance and SPF Testing for the US Market — Qalitex Laboratories offers ISO 17025-accredited SPF testing under FDA protocols for European brands entering the American suncare market
• Sunscreen and SPF Product Registration Under Health Canada for European Brands — Androxa outlines the Drug Identification Number (DIN) requirements European sunscreen brands face when entering the Canadian market